Human VEGFR2/KDR ELISA Kit

Several studies have reported that endothelial colony-forming cells (ECFCs) have an auxo-action on ischemic injury. Previous studies have found a possible correlation between this effect and the paracrine effects of ECFCs; however, their specific influencing factors and the mechanism of action are unknown and need further research. In the present study, we isolated and cultivated ECFCs from human umbilical cord blood and identified the cells. The differential cytokine expression of ECFC conditioned medium (ECFC-CM) with various culture times and conditions was detected in human umbilical cord blood, and we observed the effect of ECFC-CM on proliferation, migration, tube formation, and angiopoietic ability of human umbilical vein endothelial cells (HUVECs) by CCK-8 assay, cell scratch test, and Matrigel tube assay. Cytokines in serum-free ECFC-CM were detected using antibody microarrays; ECFC-CM under normoxic conditions was used for comparison. According to experimental results, we found that the primary cultured cells grew like "paving stones", expressing CD34, KDR, and CD144. The primary cultured cells did not express CD45 and CD133, were ac-LDL uptake and UEA-I binding double positive, and could form tube-like structures in Matrigel. Thus, the characteristics of the primary cultured cells were consistent with those of ECFCs. Antibody microarray results showed that the expression of amphiregulin, osteoprotegerin, EGF, McP-2, HGF, and LAP and 33 angiogenic factors in ECFC-CM was significantly upregulated after 48 h of normoxic culture. The results of CCK-8 assay revealed that the proliferative activity of HUVECs in the experimental group was significantly higher than that in the control group (P < 0.01) at 24, 48, and 72 h. The cell scratch test revealed that the mobility of HUVECs in the experimental group at 12 and 24 h was statistically different (P < 0.01). Compared with the control group, the experimental group HUVECs could form more tubular structures on Matrigel matrix gel (P < 0.01). These results indicate that ECFCs can promote the biological activity of mature endothelial cells via paracrine effects.

Background. Cancer is a complex disease with profound genomic alterations and extensive heterogeneity. Recent studies on large-scale genomics have shed light on the impact of core oncogenic pathways, which are frequently dysregulated in a wide spectrum of cancer types. Aberrant activation of the hepatocyte growth factor (HGF) signaling axis has been associated with promoting various oncogenic programs during tumor initiation, progression, and treatment resistance. As a result, HGF-targeted therapy has emerged as an attractive therapeutic approach. However, recent clinical trials involving HGF-targeted therapies have demonstrated rather disappointing results. Thus, an alternative, in-depth assessment of new patient stratification is necessary to shift the current clinical course. Methods. To address such challenges, we have evaluated the therapeutic efficacy of YYB-101, an HGF-neutralizing antibody, in a series of primary glioblastoma stem cells (GSCs) both in vitro and in vivo. Furthermore, we performed genome and transcriptome analysis to determine genetic and molecular traits that exhibit therapeutic susceptibility to HGF-mediated therapy. Results. We have identified several differentially expressed genes, including MET, KDR, and SOX3, which are associated with tumor invasiveness, malignancy, and unfavorable prognosis in glioblastoma patients. We also demonstrated the HGF-MET signaling axis as a key molecular determinant in GSC invasion, and we discovered that a significant association in HGF expression existed between mesenchymal phenotype and immune cell recruitment. Conclusions. Upregulation of MET and mesenchymal cellular state are essential in generating HGF-mediated therapeutic responses. Our results provide an important framework for evaluating HGF-targeted therapy in future clinical settings.